05 MAR 2018 

6WDWLVWLFDO$QDO\VLV3ODQ 
&OLQLFDO,QYHVWLJDWLRQ3ODQ7LWOH  (035(667KH(03ULQW¬å$EODWHDQG5(6HFW6WXG\ 
LQ3DWLHQWVZLWK0HWDVWDWLF/XQJ7XPRUV
&OLQLFDO,QYHVWLJDWLRQ3ODQ,GHQWLILHU  &,31XPEHU&29(035
&OLQLFDO,QYHVWLJDWLRQ3ODQ9HUVLRQ  9HUVLRQ
6SRQVRU/RFDO6SRQVRU $GYDQFHG$EODWLRQ6ROXWLRQV 
(DUO\7HFKQRORJLHV 
0HGWURQLF
/RQJERZ'ULYH 
%RXOGHU&286$
'RFXPHQW9HUVLRQ 9  
&RQILGHQWLDOLW\6WDWHPHQW 
7KHLQIRUPDWLRQFRQWDLQHGLQWKLVGRFXPHQWLVFRQILGHQWLDODQG WKHSURSULHWDU\SURSHUW\RI0HGWURQLF$Q\ 
GLVWULEXWLRQFRS\LQJRUGLVFORVXUHZLWKRXWWKHSULRUZULWWHQDXWKRU L]DWLRQRI0HGWURQLFLVVWULFWO\
SURKLELWHG3HUVRQVWRZKRPWKH LQIRUPDWLRQLVGLVFORVHGPXVWN QRZWKDWLWLVFRQILGHQWLDODQGWKDWLWPD\ 
QRWEHIXUWKHUGLVFORVHGE\WKHP










7KLVGRFXPHQWLVHOHFWURQLFDOO\F RQWUROOHG3ULQWHGFRSLHVDUH FRQVLGHUHGXQFRQWUROOHG
EXPRESS  Statistical  Analysis Plan, Version 3.[ADDRESS_592426] of Abbreviations  and Definitions of  Terms .............................................................. 3  
3. Introduction  ...................................................................................................................  5 
4. Study Objectives  ............................................................................................................  5 
5. Investigation Plan .......................................................................................................... 6  
6. Determination  of Sample Size .......................................................................................  6 
7. Statistical  Methods  ........................................................................................................  6 
7.1. Study Subjects  ..................................................................................................................  6 
7.1.1.  Disposition of  Subjects ..........................................................................................  6 
7.1.2.  Clinical Investigation Plan (CIP)  Deviations  .............................................................  [ADDRESS_592427] Imaging ........................................................................................................  10 
7.8. Interim Analyses  ............................................................................................................. 11 
7.9. Evaluation of Objectives  ..................................................................................................  11 
7.9.1.  Primary Endpoint  ................................................................................................ 11 
7.9.2.  Secondary  Endpoint  ............................................................................................  12 
7.10.  Safety Evaluation  ............................................................................................................  13 
7.11.  Health Outcomes Analyses ...............................................................................................  13 
7.12.  Changes  to Planned Analysis  ............................................................................................  13 
8. Validation Requirements .............................................................................................. 13 
 
 Table of Contents  
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 3 of 13 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
  
 
 
 
Version  Summary  of Changes  Author(s)/Title  
1.0 ‚Ä¢ Initial Document  Release Mei Jiang, Principal Statistician 
2.0 ‚Ä¢ Revise and reformat  based on new SOP Shannon  Song, Principal Statistician 
3.0 ‚Ä¢ Redacted proprietary information to post with 
results on CT.gov in accordance with Final 
Rule Briston Gregg, Clinical Research 
Coordinator III  
 
 
 
 
Abbreviation  Definition  
 
 
 
ADE Adverse Device Effect; Adverse event related to the use of an 
investigational medical device, including  adverse events resulting  from 
insufficient  or inadequate  instructions for use, deployment,  implantation,  
installation, or operation,  or any malfunction of the investigational medical 
device, as well as any event resulting from use error or from intentional  
misuse of the investigational medical device. 
 
 
 
AE Adverse event; Any untoward  medical occurrence,  unintended  disease or 
injury, or untoward  clinical signs (including  abnormal  laboratory  findings)  
in subjects, users or other persons, whether or not related to the 
investigational device. This includes events related to the investigational  
device or the comparator  and procedures  involved.  
 
 
ASADE Anticipated serious adverse device effect; an effect which by [CONTACT_5942], 
incidence,  severity, or outcome  has been identified in the risk analysis  
report (R0042262) . 
CIP clinical investigational plan 
CRF Case report form 
CT computed  tomography  
 
Device deficiency Inadequacy  of a medical device related to its identity, quality, durability,  
reliability, safety, or performance,  such as malfunction, misuse or use 
error and inadequate  labeling. 
EC Ethics committee (see IEC) 2. List of Abbreviations  and Definitions  of Terms 1. Version History  
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 4 of 13 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
 eCRF Electronic  case report form 
 
H&E Hematoxylin  and eosin stain routinely used to evaluate the structural  
integrity of cells 
IEC Institutional ethics committee (see EC) 
 
IFU Instructions for Use; a manual or document  accompanying  a technical  
device that describes the directions  by [CONTACT_462677], 
applied, etc. 
Investigative Site An approved,  participating study center/institution  
 
Investigator Either a principal, coordinating  or sub-investigator, unless otherwise  
specified 
IRB Institutional Review Board 
MWA microwave  ablation 
 
NADH Œ≤-nicotinamide adenine dinucleotide, reduced;  assay used to determine  
cell viability 
OR Operating  Room 
 
RDC Remote data capture; internet-based data entry system used to enter and 
store study data points 
RTP remote temperature probe 
 
SADE Serious adverse device effect; adverse device effect that has resulted in  
any of the consequences  characteristic of a serious adverse event 
 
 
 
 
 
 
 
 
SAE  
Serious adverse event; an adverse event that 
a) led to death, 
b) led to serious deterioration  in the health of the subject, that either 
resulted in 
1) a life-threatening  illness or injury, or 
2) a permanent  impairment  of a body structure  or a body 
function,  or 
3) in-patient or prolonged  hospi[INVESTIGATOR_059], or 
4) medical or surgical intervention to prevent life-threatening  
illness or injury or permanent  impairment  to a body structure  or a 
body function,  
c) led to fetal distress, fetal death or a congenital  abnormality or birth 
defect 
NOTE: Planned hospi[INVESTIGATOR_272] a pre-existing condition,  or a procedure  
required by [CONTACT_5745], without serious deterioration  
in health, is not considered  a serious adverse event. 
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 5 of 13 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
  
TEAE Treatment -emergent  adverse event; any event not present prior to the 
initiation of the treatments  or any event already present that worsens in 
either intensity or frequency  following exposure  to the treatments.  
 
[LOCATION_003]DE Unanticipated  serious adverse device effect; serious adverse device effect 
which by [CONTACT_5942], incidence,  severity or outcome  has not been identified  
in the current version of the risk analysis report. 
 
 
 
The EMPRESS  study is a post market prospective,  non-randomized,  single-arm, multicenter  study, 
designed  to demonstrate  dose response  of the Emprint‚Ñ¢  Ablation System using a percutaneous  approach  
in patients with metastatic  or primary lung tumors. 
This document  provides a detailed description of the statistical methods  and procedures to be 
implemented  during the analysis of the study. 
The proposed  methods  and approaches  to the data analysis should be viewed as flexible if the data 
suggest and warrant deviations from this plan. However, any deviations from this analysis plan must be 
substantiated by a sound statistical rationale and documented  in the final clinical study report. This 
statistical analysis plan (SAP) is based on version [ADDRESS_592428] market prospective,  non-randomized,  single-arm, multicenter  study. 
Ablations  will be carried out using a percutaneous  approach  at a dose (power and time setting) selected 
during procedure  planning.  The procedure  planning  application will be used as an adjunct planning tool. 
While the physician prescribes the dose, the Emprint‚Ñ¢  Procedure  Planning  Application overlays the 3- 
dimensional predicted  ablation zone on the patient CT images, facilitating visualization of the predicted  
ablation zone relative to the target tumor. Once the ablation procedure  is complete,  the scheduled  
surgical tumor resection will be performed.  
 
 
 
No formal sample size estimates were conducted  for this post-market, prospective,  non-randomized,  6. Determination of  Sample Size 5. Investigation Plan  4. Study Objectives  3. Introduction  
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 6 of 13 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
 single-arm, multicenter  study. Up to 30 subjects who are scheduled for resection of metastatic  or 
primary lung tumor(s)  will be enrolled.  Ablations will be carried out using a percutaneous  approach  at a 
dose (power and time setting) selected during procedure  planning.  Up to [ADDRESS_592429] disposition (e.g., number completing the study, number lost-to-follow-up) will be summarized  
with frequency  tables. The following information will be provided  by [CONTACT_3885]: 
‚Ä¢ Number and percentage  of screen failures 
‚Ä¢ Number and percentage  of enrolled subjects 
‚Ä¢ Number and percentage  of subjects who have completed  the Emprint‚Ñ¢  ablation procedure  
‚Ä¢ Number and percentage  of subjects who have completed  the Emprint‚Ñ¢  ablation procedure  and 
the Primary Endpoint  
‚Ä¢ Number and percentage  of subjects who have completed  the Emprint‚Ñ¢  ablation procedure  and 
the Secondary  Endpoint  
‚Ä¢ Number and percentage  of subjects who have completed  the postoperative evaluation / end of 
study Visit 
‚Ä¢ Number and percentage  of subjects who exited the study, overall and by [CONTACT_462678] 
 
7.1.2. Clinical Investigation  Plan (CIP) Deviations  
A CIP deviation  is defined as an event where the Investigator or study personnel  did not conduct 
the study according  to the CIP. Deviations  shall be reported regardless of whether medically justifiable or 
taken to protect the Subject in an emergency.  
 
Except a change that is intended  to eliminate an immediate hazard to a Subject, the protocol will be 
followed as described.  Subject specific deviations and non-Subject specific deviations  will be reported.  
Investigators will also adhere to procedures  for reporting study deviations to their IRB in accordance  with 
their specific IRB reporting policies and procedures.  
 
7.1.3. Analysis Sets  
In general, data analysis will be conducted  on all subjects who are enrolled in the trial and undergo the 
ablation procedure  using the Emprint‚Ñ¢  system. 
Intent-To-Treat (ITT): subjects enrolled into the study. 
 
Modified ITT (MITT): ITT subjects who completed  the ablation procedure.  If all ITT subjects completed  
the ablation procedure,  then the ITT population is the same as the MITT population.  
Additional  analysis sub-populations  may be defined per scientific research  need. 7. Statistical  Methods  
EXPRESS  Statistical  Analysis Plan, Version 3.[ADDRESS_592430] will be used as the day of the start date  
unless the imputed date would before the procedure  in which case the procedure  date will be used for 
the start date of the adverse event. 
For baseline ca tegorical variables, ‚Äúunknown‚Äù responses will be counted as not having the characteristic  
and will be included in the denominator.  Missing values will not be counted in rate denominators.  
 
7.5. Adjustments  for Multiple  Comparisons  
Not applicable since no statistical test will be performed  on the primary or secondary endpoint.  
 
7.6. Demographic  and Other Baseline  Characteristics  
Continuous  variables will be summarized  with number of subjects (n), mean, standard  deviation,  median, 
and ranges. The frequency  distributions  (counts and percentages)  will be given for categorical  data. 
EXPRESS  Statistical  Analysis Plan, Version 3.[ADDRESS_592431] demographic  data will be summarized.  
‚Ä¢ Age 
‚Ä¢ Gender 
‚Ä¢ Ethnicity  
‚Ä¢ Race 
‚Ä¢ Height 
‚Ä¢ Weight 
 
7.6.2. Smoking  History  
The following smoking history data will be summarized:  
‚Ä¢ History of tobacco use (Yes/No,  if yes, current/former)  
‚Ä¢ Tobacco use: type of tobacco, duration of use, # of units, and use frequencies  
 
7.6.3. Cancer Diagnosis  
The following cancer diagnosis data will be summarized:  
‚Ä¢ Primary cancer type 
‚Ä¢ Tumor pathology  
‚Ä¢ Months since primary cancer diagnosis 
‚Ä¢ Target tumor type 
‚Ä¢ Location of target tumor 
‚Ä¢ Prior cancer treatments  
o Cancer type 
o Years of since previous cancer diagnosis 
o Cancer treatment 
o Months since last cancer treatment 
 
7.6.4. Medical  History 
The following medical history data will be summarized:  
‚Ä¢ Has the patient ever had surgery in the thoracic space? (unrelated  to Lung Cancer 
treatment)  
‚Ä¢ Previous lung disease diagnosis
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 9 of 13 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
  
7.7. Treatment  Characteristics  
Continuous  variables will be summarized  with number of subjects (n), mean, standard  deviation,  median, 
and ranges. The frequency  distributions  (counts and percentages)  will be given for categorical  data 
 
7.7.1. Planning  Application  
Planning application characteristics: 
‚Ä¢ Axial two-dimensional measurement  - maximum  axial length 
‚Ä¢ Axial two-dimensional  measurement - perpendicular  axial length associated within  
maximum  axial length 
‚Ä¢ Planned antenna point of entry (intercostal space) 
‚Ä¢ Planned approach  
‚Ä¢ Planned ablation time 
‚Ä¢ Planned ablation power 
‚Ä¢ Planned tip distance 
‚Ä¢ Planned insertion depth 
‚Ä¢ Target tumor width (X) 
‚Ä¢ Target tumor height (Y) 
‚Ä¢ Target tumor depth (Z) 
‚Ä¢ Calculated target tumor volume from planning application 
‚Ä¢ Predicted  ablation zone width (X) 
‚Ä¢ Predicted  ablation zone height (Y) 
‚Ä¢ Predicted  ablation zone depth (Z) 
‚Ä¢ Predicted  ablation zone volume 
‚Ä¢ Predicted  minimum margin 
‚Ä¢ Predicted  maximum  margin
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 10 of 13 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
  
7.7.2. Ablation  Procedure  
Procedural  characteristics: 
‚Ä¢ Duration  of anesthesia  (min) 
‚Ä¢ Type of anesthesia 
‚Ä¢ Duration  of antenna placement  (min) 
‚Ä¢ Antenna length 
‚Ä¢ Number of passes through the gantry for placement  
‚Ä¢ Actual approach  
‚Ä¢ Duration  of ablation time (min) 
‚Ä¢ Actual ablation power 
 
7.7.3. CT Imaging  
CT imaging characteristics: 
‚Ä¢ Pre-procedure  image quality 
‚Ä¢ Lesion location 
‚Ä¢ Longest axial diameter  
‚Ä¢ Perpendicular  diameter  
‚Ä¢ Tumor volume 
‚Ä¢ Critical structures  within 10mm of tumor border 
‚Ä¢ Distance from tumor 
‚Ä¢ Intra-procedural  image quality 
‚Ä¢ Radiating section of antenna of tumor center 
‚Ä¢ Tip to tumor margin 
‚Ä¢ Post-procedural  image quality 
‚Ä¢ Ablation zone Width x 
‚Ä¢ Ablation zo ne Width y
‚Ä¢ Ablation zone  Depth z 
‚Ä¢ Tip distance 
‚Ä¢ Calculated ablation  zone volume 
‚Ä¢ Needle depth 
‚Ä¢ Ablation zone shape
 
EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 11 of 13 
 
 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
 ‚Ä¢ Presence  of cavitation  
‚Ä¢ Maximum  margin 
‚Ä¢ Minimum margin 
‚Ä¢ Location of areas with margins less than 0.5mm 
7.8. Interim  Analyses  
Interim analyses will be conducted  once the first [ADDRESS_592432]-procedure  and prior to surgical resection and is 
defined as the percentage change from the predicted  outcome  to the actual outcome.  
The predicted  values are from the PLAN CRF: 
‚Ä¢ Predicted  ablation zone width (X) 
‚Ä¢ Predicted  ablation zone height (Y) 
‚Ä¢ Predicted  ablation zone depth (X) 
‚Ä¢ Predicted  ablation zone volume 
‚Ä¢ Calculated ablation zone volume (calculated from predicated X, Y, and Z value) 
The actual values are from the IMAGE CRF: 
‚Ä¢ Width (X) 
‚Ä¢ Height (Y) 
‚Ä¢ Depth (X)  
 
  

EXPRESS  Statistical  Analysis Plan, Version 3.0 Page 12 of 13 
 
 
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential   
 The percentage  change (calculated  as 100*(A-P)/P) (where P=predicted  and A=actual) will be calculated  
for each of the following measurements:  
‚Ä¢ Ablation zone width (X) 
‚Ä¢ Ablation zone height (Y) 
‚Ä¢ Ablation zone depth (Z) 
‚Ä¢ Ablation zone volume 
ÔÉº Predicated  ablation zone volume vs actual ablation zone volume 
ÔÉº Calculated ablation zone volume (calculated from predicated X, Y, and Z value) 
vs. actual ablation zone volume 
‚Ä¢ Ablation zone shape 
 
For each of the above measurements,  the percentage  change will be summarized  with number of 
subjects (n), mean, standard  deviation,  median, and ranges. Summary  will be done for all target tumors 
combined  and for each target tumor type (primary,  recurrent,  and metastatic).  
 
7.8.2. Secondary  Endpoint  
Complete  tumor ablation immediately  post-procedure  will be measured  for each target tumor using 
histologic analysis to evaluate complete ablation at the cellular level. 
All histology  samples will be evaluated  by a core laboratory.  Both vital staining (Nicotinamide adenine 
dinucleotide  (NADH) assay) and structural staining (hematoxylin  and eosin; H&E) techniques  will be used 
to evaluate cellular integrity within the ablation zone. 
The histology data for the NADH assay is from the NADH Sample Analysis ‚Äì Part 1 of the PATHOLOGY  
CRF: 
ÔÉò If the ‚ÄúEvidence  of Complete  Ablation‚Äù  is checked Yes, it is complete  tumor ablation 
ÔÉò If the ‚ÄúEvidence  of Complete  Ablation‚Äù  is checked No and the ‚ÄúIf No, Was Delayed Necrosis 
Achieved‚Äù  is checked Yes, it is delayed necrosis 
ÔÉò If the ‚ÄúEvidence  of Complete  Ablation‚Äù  is checked No and the ‚ÄúIf No, Was Delayed Necrosis 
Achieved‚Äù  is checked No, it is incomplete tumor ablation 
 
The histology data for the H&E assay is from the H&E Sample Analysis ‚Äì Part 2 of the PATHOLOGY  CRF: 
ÔÉò If the ‚ÄúEvidence  of Complete  Ablation‚Äù  is checked Yes, it is complete  tumor ablation 
ÔÉò If the ‚ÄúEvidence  of Complete  Ablation‚Äù  is checked No, it is incomplete tumor ablation 
 
 
The number and percentage  of tumors which achieve complete tumor ablation, delayed necrosis and 
incomplete tumor ablation for all target tumors combined  and for each target tumor type (primary,  
recurrent,  and metastatic)  will be provided.  The summary  will be provided  by [CONTACT_462679], H&E assay, 
and NADH and H&E combined.  
  
This document  is electronically  controlled.  Printed copi[INVESTIGATOR_462676].  
Confidential  EXPRESS  Statistical  Analysis Plan, Version 3.[ADDRESS_592433] of the tables, listings  
and figures will be validated by [CONTACT_408170]. 
Level I: The peer reviewer  independently  programs output and then compares  the output with that 
generated  by [CONTACT_408171].  Define the level of validation required for each 
objective  or analysis output. 
 
Level II: The peer reviewer  reviews the code; where appropriate,  performs  manual calculations  or simple 
programming checks to verify the output. 8. Validation Requirements  